Top Story

FDA approves opioid with abuse-deterrent properties

November 21, 2014

The FDA has approved an extended release hydrocodone bitartrate, an opioid analgesic to treat severe chronic pain.

Hydrocodone bitartrate (Hysingla ER, Purdue Pharma) has some properties that may deter abuse because it is difficult to break, crush or dissolve and becomes a viscous gel that is difficult to inject when dissolved. Abuse and overdose, however, still are possible. It is intended only for pain that requires daily, 24-hour, long-term treatment and is not intended to be taken as needed.

NIH renews research grants on aging

November 20, 2014
The NIH has announced renewed funding of $23.4 million for 11 Edward R. Roybal Centers for Research on Applied Gerontology and the designation of two additional…
Meeting News Coverage

Omega-3 supplements may delay psychosis onset in high-risk patients

November 20, 2014
Omega-3 fatty acid supplementation may have a protective effect against progression to psychosis for approximately 7 years in individuals at very high risk for the…
Industry News

HHS, NIH propose changes to make more clinical trial data available

November 19, 2014
The Department of Health and Human Services and the National Institutes of Health are releasing two proposals for public comment designed to increase the transparency of…
More News Headlines »
CNE Quiz

How to Obtain Contact Hours by Reading Articles in This Issue

Journal of Psychosocial Nursing and Mental Health Services, November 2014, Volume 52 Issue 11
More »
CME
Psych Forum 2014 Highlights

Psych Forum 2014 Highlights

Schizophrenia is a common and serious disabling mental illness, estimated to affect 24 million people worldwide…
More »
Meeting News Coverage Video
thumbnail for video 3790501525001

Experts debate PANDAS diagnosis in children

September 18, 2014
WASHINGTON, D.C. — Margaret K. Hostetter, MD, the B. K. Rachford professor and chair of department of…
More »
morganatic-roan
morganatic-roan